Key Takeaways: The $38 Billion Shockwave

  • The Surge: TerrAscend Corp. (TSX: TSND) stock experienced a massive, high-volume surge of over 84% on Friday, December 12, 2025, as investors piled into U.S. cannabis Multi-State Operators (MSOs).
  • The Unprecedented Catalyst: The primary driver was explosive, late-breaking news that the U.S. administration is moving to reclassify (reschedule) cannabis from a Schedule I to a Schedule III controlled substance.
  • The Financial Game-Changer: This federal move is expected to dramatically reduce the punitive 280E tax burden on U.S. cannabis companies, instantly unlocking billions in potential cash flow and profitability for TerrAscend and its peers.

What Ignited the 84%+ Frenzy? Rescheduling is the Spark

TerrAscend’s dramatic one-day price movement is a direct result of the market pricing in the single most important regulatory change for the industry in decades: federal cannabis rescheduling.

  1. The Federal Reform Megatrend

Reports confirming President Donald Trump is poised to enact an executive order directing cannabis to be moved from Schedule I to Schedule III under the Controlled Substances Act sent the entire MSO sector soaring.

  • The 280E Windfall: The move to Schedule III is expected to end the infamous IRS Code 280E, which currently prevents cannabis businesses from deducting standard business expenses. For profitable MSOs, this change translates directly into a massive boost to free cash flow.
  • Mainstream Validation: While not full legalization, Schedule III is a pivotal step that acknowledges the medical utility of cannabis, paving the way for easier access to banking, research, and potential listing on major U.S. exchanges.

Source: Kalkine Group

  1. Analyst Confidence and Strategic Execution

The federal tailwind found fertile ground in TerrAscend, a company already executing a disciplined strategy focused on profitability.

  • Improved Outlook: Positive analyst commentary, amplified by the rescheduling news, focused on the company's trajectory toward breaking even and achieving significant margin expansion through operational leverage.
  • Focused Portfolio: Investors are rewarding the company’s recent strategic decisions, including its May 2025 entry into Ohio and its June 2025 exit from the less-profitable Michigan market to concentrate resources on core, high-growth states like New Jersey and Maryland.

TerrAscend’s Core Strategy & Financial Discipline

As a prominent North American MSO, TerrAscend's strategy is centered on vertical integration in key, limited-license markets. The market's enthusiasm is a vote of confidence in its shift toward efficiency.

Source: Company Data

The Momentum vs. The Reality Check

The over 84% surge in TSND is a spectacular momentum-driven rally, perfectly illustrating the immense upside potential baked into the US cannabis sector based on regulatory hopes.

Risks on the Horizon

  1. Regulatory Execution Risk: While the news is strong, the final execution of the Schedule III change is not yet complete. Any unexpected delays or changes in the final rule could trigger a sharp correction.
  2. Volatile Sector: The cannabis industry remains inherently volatile. Price spikes driven by speculation and short-covering can be followed by equally swift pullbacks.
  3. Profitability and Debt: Despite strong progress, the company still operates with a history of losses and carries a notable level of debt, a common hurdle in the capital-restricted cannabis space. 

Conclusion

The market has now decisively valued TerrAscend based on the fundamental improvement that federal rescheduling promises. The company’s long-term success hinges on the completion of the Schedule III move and its continued flawless execution on its cost-cutting and market-optimization strategy.

Source: Trading View, 12 December 2025